Characteristics of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of JAK2 Inhibitor Ruxolitinib
Lucia Masarova, M.D. presents from ASH 2017 on validation of the MYSEC prognostic model in patients with post-PV and post-ET myelofibrosis.
Recent Video
Most Popular
Specialties :                    Search : is a member of the Oncology.TV family of oncology medical education websites. offers specialists, primary care physicians, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including interactive case based presentations), news and information about Myeloproliferative Neoplasms (MPNs).